Research Article

Nrf2-Mediated Ferroptosis Inhibition Exerts a Protective Effect on Acute-on-Chronic Liver Failure

Jing Wu,1 Ran Xue,2 Muchen Wu,1 Xuehong Yin,1 Bangxiang Xie,3 and Qinghua Meng1

1Department of Liver Disease, Beijing You-An Hospital, Capital Medical University, Beijing 100069, China
2Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Gastrointestinal Oncology, Peking University Cancer Hospital & Institute, Beijing 100036, China
3Beijing Youan Hospital, Beijing Institute of Hepatology, Capital Medical University, Beijing 100069, China

Correspondence should be addressed to Bangxiang Xie; yhxych7201@ccmu.edu.cn and Qinghua Meng; meng_qh0805@ccmu.edu.cn

Received 17 November 2021; Revised 17 January 2022; Accepted 14 March 2022; Published 16 April 2022

Academic Editor: Karolina Szewczyk-Golec

Copyright © 2022 Jing Wu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Although massive hepatocyte cell death and oxidative stress constitute major events of acute-on-chronic liver failure (ACLF), the relationship of ferroptosis with ACLF has yet to be explored. Nuclear factor erythroid 2-related factor 2 (Nrf2) is a key regulator of ferroptosis. However, if Nrf2 modulates ACLF through ferroptosis remains unknown. Here, the liver tissues of ACLF patients were collected and murine models of ACLF using carbon tetrachloride, D-galactosamine, and lipopolysaccharide as well as an H2O2-induced hepatocyte injury model were established. Upon ACLF, livers exhibited key features of ferroptosis, including lipid peroxidation (increase in malondialdehyde whereas a decrease in glutathione and nicotinamide adenine dinucleotide phosphate), and increased mRNA expression of prostaglandin-endoperoxide synthase-2 (PTGS2). Ferroptosis inducer RSL-3 treatment aggravated liver damage, while ferroptosis inhibitor Ferrostatin-1 administration alleviated ACLF severity, manifesting with improved liver histopathological lesions and reduced serum ALT and AST. Compared with normal liver tissue, Nrf2 was upregulated in ACLF patients and murine models. Pharmacological activation of Nrf2 (Bardoxolone Methyl) attenuated liver damage, prevented lipid peroxidation, upregulated PTGS2 mRNA expression, and improved ferroptosis-specific mitochondrial morphology in vivo. In contrast, Nrf2 inhibitor ML385 exacerbated lipid peroxidation and liver injury. Collectively, Nrf2 plays a protective role in ACLF progression through repressing ferroptosis, which provides promising therapeutic cues for ACLF.

1. Introduction

Acute-on-chronic liver failure (ACLF) is a distinct clinical entity when chronic liver disease undergoes acute insults. ACLF is complicated with organ failures, characterized by rapid deteriorated course and high short-term mortality [1]. Globally, it is estimated that 24% to 40% of patients with cirrhosis admitted to hospitals were diagnosed with ACLF [2]. Deciphering ACLF pathogenesis and developing therapeutic strategies have become unmet needs and critical priority. Nevertheless, molecular mechanisms of progressive liver failure have hitherto not been fully understood, and ACLF remains one of the most challenging problems in clinic. Therefore, intense research efforts to delay disease progression are urgently required.

Hepatic cell death is a crucial molecular event of ACLF. Although apoptosis [3], autophagy [4], and necrosis [5] have been proposed in ACLF, whether other types of cell death are pathophysiological mechanisms underlying ACLF has not been explored. Ferroptosis is a novel mode of iron-dependent cell death manifesting with overwhelming lipid peroxidation and loss of cellular redox homeostasis [6].
Ferroptosis is morphologically, genetically, and biochemically distinct from other types of cell death [7, 8]. Accumulating evidence suggests that ferroptosis plays an unrecognizable role in regulating disease development and progression, including neoplastic [9], neurological [10], and heart diseases [11]. Given that the liver is highly predisposed to oxidative damage and iron accumulation has been involved in multiple liver diseases [12], ferroptosis is a potential contributor to various liver diseases. Dysregulated iron homeostasis has been reported in patients with ACLF [13]. Specifically, increased circulating levels of total iron and ferritin were observed in ACLF patients relative to normal controls. Since aberrant iron metabolism is a potential predictor of multiorgan failure and mortality in patients with ACLF [13, 14], we hypothesized that ferroptosis contributed to ACLF pathogenesis. To the best of our knowledge, there has been no clear demonstration of association between ferroptosis and ACLF.

The nuclear factor erythroid 2-related factor 2 (Nrf2) is a vital nuclear transcription factor, which controls a battery of cellular defensive genes to maintain redox homeostasis and cell survival [15]. Recently, Nrf2 has been identified as a regulator of ferroptosis. For example, in neoplastic diseases, Nrf2-mediated ferroptosis suppressed tumor growth and sensitized cancer cells to antitumor drugs [16, 17]. In acute or chronic tissue/cell damage, Nrf2 stabilization could restrain ferroptosis and subsequently relieve injury [18]. Specifically, activation of Keap1/Nrf2-ARE signaling pathway in response to dehydrobiotic acid could eliminate reactive oxygen species (ROS) accumulation and suppress ferroptosis, which consequently, improved nonalcoholic fatty liver disease [19]. However, little is known whether ferroptosis is a mechanism through which Nrf2 confers a protective effect on ACLF.

The purpose of this study was to investigate if ferroptosis participates in ACLF pathogenesis and to unveil underlying molecular mechanisms. Major features of clinical ACLF were recapitulated through establishing murine models with carbon tetrachloride (CCl4), D-galactosamine (D-gal), and lipopolysaccharide (LPS). A hepatocyte injury model was established by treating L02 cells with H2O2 in vitro. Successful establishment of ferroptosis activation: mice were administrated i.p. with ferroptosis inducer RSL-3 (10 mg/kg, Abmole, USA) three times a week for 4 weeks. Group 4 (n = 6), ACLF + ferroptosis activation: mice were administrated i.p. with ferroptosis inducer ML385 (30 mg/kg, Abmole, USA) four times per week for 4 weeks. Group 5 (n = 6), ACLF + Baroxolone Methyl (BM): mice were administrated with BM (10 mg/kg, dissolved in olive oil, Abmole, USA) by gavage once every other day for 4 weeks. Group 6 (n = 6), Baroxolone Methyl alone: mice were treated with i.p. injection of Fer-1(10 mg/kg, Abmole, USA) three times a week for 4 weeks. The experimental regimen was described in Figure 1.

2.2. Patients. Between January 2019 and June 2021, five transplant recipients who fulfilled diagnostic criteria of Asian Pacific Association for the Study of the Liver (APASL) [20] for ACLF were included in this study. Normal liver tissues were obtained from liver transplant donors, serving as the healthy control. Exclusion criteria included multiple organ failure, fulminant hepatic failure, complicated liver cancer, long-term immunosuppressive therapy, and age less than 18 years. Informed consent was obtained from each participant before enrollment. This study was approved by the Ethical Committee of Beijing You-An Hospital, Capital Medical University (No. LL-2018-119-K).

2.3. Western Blot. The cells and liver tissues were lysed in lysis buffer and centrifuged at 4°C and 12000 rpm for 30 min. Nuclear proteins were extracted with the Nuclear Protein Extraction Kit (Solarbio, China). After assessment of concentrations, proteins were denatured using 5× sodium dodecyl sulfate (SDS) loading buffer at 100°C for 5 min. Protein mixtures were separated on 8-12% SDS-polyacrylamide gel electrophoresis and transferred to polyvinylidene difluoride membrane. After blocked with 5% defat milk at room temperature for 1 h, the membrane was incubated with the primary antibody against Nrf2 (Cell Signaling Technology, MA, USA), HO-1 (Abcam, Cambridge, UK), and NQO1 (Abcam, Cambridge, UK) overnight at 4°C. The next day, after washed for three times with Tris Buffered Saline with Tween 20 (TBST), the membrane was incubated with goat antirabbit horseradish peroxidase-conjugated secondary antibodies.
(Cell Signaling Technology, MA, USA) for 1 h at room temperature and washed for three times with TBST. Subsequently, the bands were visualized using an enhanced chemiluminescence detection kit (Thermo Fisher Scientific, USA) according to the manufacturer’s instructions.

2.4. Liver Histopathology and Immunohistochemical Assays. As previously described [21], the liver tissues collected from different groups were fixed with formaldehyde and embedded in paraffin. Haematoxylin–eosin and Masson’s trichrome staining were conducted to evaluate liver histological features and tissue fibrosis. Formalin-fixed paraffin-embedded liver tissues were stained with antibodies against Nrf2 (Sigma-Aldrich, St. Louis, MO, USA). The morphology was assessed under an electron microscope (Nikon Eclipse 80i, Tokyo, Japan). Representative pictures of liver sections from all groups were displayed.

2.5. Enzyme-Linked Immunosorbent Assay (ELISA). ELISA kits (RayBiotech, Norcross, GA) were applied to detect hepatic protein levels of IL-6 and tumor necrosis factor (TNF)-α according to the manufacturer’s protocol.

2.6. Serum Biochemistry. Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were detected by an automated chemical analyzer (Olympus Company, Tokyo, Japan).

2.7. Hepatic Content of Malondialdehyde (MDA) and Glutathione (GSH). According to the manufacturer’s recommendations, MDA and GSH levels were measured using corresponding detection kits (Beyotime, Beijing, China). Absorbance values of samples were measured at 532 nm and 412 nm, respectively.

2.8. Iron Assay. Hepatic iron concentration was determined by Iron Assay Kit (No. ab83366, Abcam) according to the manufacturer’s instruction.

2.9. Cell Culture. Human cell line L02 was cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) (Gibco, Gaithersburg, MD, USA) containing 10% fetal bovine serum (FBS) (Gibco, Gaithersburg, MD, USA) and grown at 37°C and 5% CO₂ humidified atmosphere. Cells were treated with H₂O₂ (300 μM) (Invitrogen, Carlsbad, CA, USA) for 30 h for

Figure 1: The experimental regimen applied in this study.

| Gene     | Forward       | Reverse       |
|----------|---------------|---------------|
| PTGS2    | 5′-TGAGCATCTACGGTTTGCTG-3′ | 5′-TGTTGTCTGGAACAACCTGC-3′ |
| GAPDH    | 5′-TGTCATGGCAAGTACCTG-3′ | 5′-GTGAACGCGCTCGCTCG-3′ |
| HO-1     | 5′-CCAGGCAGAGAATGCTGAGTTTC-3′ | 5′-AAGACTGGGCTCTCCTTG-GC-3′ |
| NQO-1    | 5′-CCTGCGATTTGCTGAAGCTG-3′ | 5′-GTGGTATGGAAGCCTG-3′ |

Table 1: Primers used in this study.
Hepatic iron content (µM/g protein)

(a) Hepatic NADPH content (µM/mg liver)

(b) PTGS2 mRNA expression

(c) Liver index (%)

(d) Figure 2: Continued.
Figure 2: Continued.
hepatocyte injury model. Moreover, cells were treated with or without inducer or inhibitor of ferroptosis or Nrf2 for mechanistic exploration.

2.10. Cell Viability Assay. Cell Counting Kit-8 (CCK-8, Abmole, USA) was used to assess proliferation of cells with different treatments. Briefly, $3 \times 10^3$ L02 cells were seeded

---

**Figure 2:** Ferroptosis aggravated liver injury in ACLF mice models. (a) Hepatic iron content both in healthy controls and ACLF patients was measured (HC $n = 3$, ACLF $n = 5$). (b) Hepatic NADPH content was decreased in ACLF patients relative to healthy controls (HC $n = 3$, ACLF $n = 5$). (c) PTGS2 mRNA expression was increased in patients with ACLF compared with healthy controls (HC $n = 3$, ACLF $n = 5$). (d) The livers of the ACLF+RSL-3-treated mice were slightly heavier than those of ACLF mice although without statistical significance. (e) Representative images of morphologic and histopathological features of the control, ACLF, and ACLF+RSL-3-treated mice. Original magnification $\times 100$ (Bar $= 40 \mu m$) and $\times 200$ (Bar $= 20 \mu m$). (f and g) Serum ALT and AST levels and hepatic inflammatory cytokines (IL-6, TNF-α) were assessed. (h–j) Lipid peroxidation was analyzed through comparing hepatic GSH, NADPH, and MDA in the three groups. (k) The expression of PTGS2 mRNA was measured by qRT-PCR. Data are expressed as mean ± SD $p < 0.05$, $**p < 0.01$, $***p < 0.001$, $****p < 0.0001$. $n = 3$ (control, ACLF+RSL-3), $n = 6$ (ACLF). ALT = alanine aminotransferase; AST = aspartate aminotransferase; ACLF = acute-on-chronic liver failure; GSH = glutathione; IL-6 = interleukin-6; MDA = malondialdehyde; NADPH = nicotinamide adenine dinucleotide phosphate; PTGS2 = prostaglandin-endoperoxide synthase-2; qRT-PCR = quantitative real-time polymerase chain reaction; TNF-α = tumor necrosis factor alpha.
Figure 3: Continued.
in 96-well plates and incubated for 24 h. Afterwards, cells were pretreated with BM (0.2 μM), Fer-1 (0.25 μM), and ML385 (10 μM) for 12 h, respectively, and H2O2 (300 μM) for 30 h. For the positive control group, cells were treated with Erastin (E, 10 μM, an inducer of ferroptosis) for 30 h.

Later, 10 μL CCK-8 working solution was added to corresponding culture medium and incubated for 2 h at 37°C. Finally, absorbance was evaluated at 450 nm using a microplate reader.

2.11. Lipid Peroxidation Assay. Indicated cells were stained with 5 μM BODIPY® 581/591 C11 dye for 30 min at 37°C in the dark. After the incubation, cells were washed twice with phosphate buffer saline (PBS) and resuspended in 400 μL PBS. Flow cytometry analysis was conducted using a BD FACSCalibur system.

2.12. Transmission Electron Microscopy (TEM). Liver tissues were fixed with glutaraldehyde (2.5%) and washed for three times with phosphate-buffered solution. After embedded in 1% agarose, samples were dehydrated in 30%, 50%, 70%, 80%, and 95% ethanol for 20 min, in Acetone for 15 min, and then embedded in Acetone. Resin blocks were cut to 60-80 nm-thin fragments on ultramicrotome. The tissue
Hepatic MDA content (µM/g protein)

(a)

Control
ACLF
ACLF + BM

Total GSH content (µM/g liver)

(b)

Control
ACLF
ACLF + BM

Hepatic NADPH content (nM/g liver)

(c)

Control
ACLF
ACLF + ML385

Relative PTGS2 expression

(d)

Control
ACLF
ACLF + BM

Figure 4: Continued.
was signifi-

cantly increased in ACLF (Figure 2(a)), consistent with previous studies [13]. Decreased hepatic nicotinamide adenine dinucleotide phosphate (NADPH) content, an established signature of ferroptosis [22, 23], was observed in ACLF relative to the healthy controls (Figure 2(b)). In addition, the mRNA expression of prostaglandin-endoperoxide synthase-2 (PTGS2), another typical feature of ferroptosis [22], was elevated in ACLF (Figure 2(c)). We speculated that ferroptosis was implicated in ACLF pathogenesis.

To verify this hypothesis, a mouse model was established to recapitulate major characteristics of clinical ACLF using CCl4, LPS, and D-gal (Figure 1). Induction of ferroptosis, through treatment with RSL-3, an inducer of ferroptosis [24], reinforced liver damage. As shown in Figures 2(d) and 2(e), in the control group, the livers were smooth and rosy with intact hepatic structure; while in the ACLF group, the livers were smaller and harder, with blunt edges and small nodules. Disordered hepatic lobule structure, substantial hepatic cell death, and advanced fibrosis with nodule formation, as major characteristics of ACLF [1], were observed in the successfully established ACLF group. Of note, these histopathological lesions were more evident in the livers of RSL-3-treated mice. Consistent with an increase in histopathological severity, serum biochemical indicators (ALT and AST) were elevated in response to RSL-3 treatment (Figure 2(f)). Regarding inflammatory cytokines, however, no significantly increased hepatic IL-6 and TNF-α were observed in response to RSL-3 treatment compared with the ACLF group (Figure 2(g)). In parallel with aggravated liver damage, several indicators of lipid peroxidation, (a) MDA (Figure 2(h)), an end product of lipid peroxidation, was higher in the ACLF group and the highest in the RSL-3 treatment group; (b) GSH and NADPH showed an opposite trend (Figures 2(i) and 2(j)). Similarly, the mRNA expression of PTGS2 was elevated along with increased

**FIGURE 4**: Activation of Nrf2 mitigated lipid peroxidation. (a) Hepatic MDA content was measured in all three groups. (b) Total GSH concentration was detected. (c) Hepatic NADPH content was measured. (d) The relative mRNA expression of ferroptosis-related gene PTGS2 was measured in all three groups. (e) Increased mitochondrial outer membrane rupture and diminished mitochondrial ridges were observed in the ACLF group under electron microscopy, while BM treatment improved these morphological changes. Bar = 10 μm. Black arrows indicate normal mitochondria; red arrows indicate shrunken and ruptured mitochondria. *p < 0.05, **p < 0.01, ***p < 0.001. n = 3 (control), n = 6 (ACLF), n = 5 (ACLF+BM). ACLF = acute-on-chronic liver failure; BM = bardoxolone methyl; GSH = glutathione; MDA = malondialdehyde; NADPH = nicotinamide adenine dinucleotide phosphate; Nrf2 = nuclear factor erythroid 2-related factor 2; PTGS2 = prostaglandin-endoperoxide synthase-2.
Figure 5: Continued.
(c) Figure 5: Continued.
severity of liver injury in the ACLF and RSL-3 groups (Figure 2(k)). Collectively, ferroptosis might act as a deleterious factor, which aggravated liver damage and promoted disease progression in ACLF.

3.2. Activation of Nrf2 Inhibited Ferroptosis and Ameliorated Liver Injury In Vivo. Nrf2-mediated defensive network might protect against various pathologic injuries and engage in regulating ferroptosis [25]. When being activated, Nrf2 was translocated to nuclear and initiated downstream antioxidative genes [26, 27]. Our preliminary results showed that nuclear protein expressions of Nrf2 were significantly increased in the liver tissues of ACLF patients compared with normal ones (Figure 3(a)). In addition, at mRNA levels, NAD(P)H quinone dehydrogenase, quinone 1 (NQO1), a pivotal target gene of Nrf2, was upregulated in ACLF liver tissues compared with normal ones (Supplemental Figure 1). Therefore, we speculated that Nrf2 might have a protective role in ferroptosis-provoked liver damage. BM is a common agent to activate Nrf2 [28, 29]. Nrf2 was activated in vivo in the BM group, as revealed by increased nuclear protein expression of Nrf2 relative to the ACLF group (Figure 3(b)). As expected, immunohistochemical staining of Nrf2 showed the same results as western blots (Figure 3(c)). Specifically, in the control group, a small proportion of Nrf2 positive cells were diffusely distributed in the cytoplasm. In contrast, in the ACLF group, a large proportion of Nrf2 positive cells in the nuclei were identified. In the BM group, Nrf2 expressed in nuclei was largely augmented. Alongside Nrf2 activation was attenuated severity of ACLF, which was confirmed by gross morphological and histopathological features of the livers (Figure 3(d)). Specifically, Nrf2-activated livers demonstrated mitigated inflammation and hepatocytes death along with improved hepatic lobule structure disorder. In addition, this pattern was confirmed by decreased hepatic inflammatory indicators, such as IL-6 and TNF-α (Figure 3(e)). Contrary to our expectation, BM treatment failed to reduce the serum levels of ALT and AST (Figure 3(f)).

Furthermore, the potential role of Nrf2 in ferroptosis during ACLF was examined. As shown in Figures 4(a)–4(c), BM increased hepatic content of GSH and NADPH whereas decreased content of MDA. In addition, PTGS2 was downregulated in response to BM treatment (Figure 4(d)). Apart from lipid peroxidation, mitochondrial morphology was examined. Compared to the control group, the liver tissues from the ACLF group displayed smaller mitochondria morphology with diminished mitochondria cristae, as well as rupture of outer mitochondrial membrane, all of which were specific morphological features of ferroptosis [7], whereas BM treatment improved this morphological phenotype (Figure 4(e)). Accordingly, Nrf2 activation inhibited ferroptosis, which might hold a substantial potential in attenuating liver damage in ACLF.
Figure 6: Continued.
Figure 6: Continued.
PTGS2 was decreased in mice treated with Fer-1. (h) Fer-1 treatment improved ferroptosis-specific mitochondrial morphology. Bar = 10 μm. Black arrows indicate normal mitochondria; red arrows indicate shrunken and ruptured mitochondria. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001. 

3.3. Nrf2 Inhibition Promoted the Onset of Lipid Peroxidation and Corresponded to a More Severe Liver Injury. To verify that Nrf2 was required in improving lipid peroxidation and liver damage, ML385, an inhibitor of Nrf2 [30], was used to inactivate Nrf2. As demonstrated by western blot, nuclear content of Nrf2 was decreased, confirming inactivation of Nrf2 (Figure 5(a)). Consistent with decrease in Nrf2, more severe histopathologic lesions, such as hepatocytes necrosis, destruction of the lobular structure, infiltration of inflammatory cells, obvious vascular congestion, and hemorrhage and tissue fibrosis were observed in the ML385 group compared to the ACLF group (Figure 5(b)). Convergently, liver damage assessed by serum biochemical parameters including ALT and AST was exacerbated in the ML385-treated mice (Figure 5(c)). As Nrf2 inhibited inflammatory response, inflammatory factors including IL-6 and TNF-α were augmented in the Nrf2-inhibited livers (Figure 5(d)). As for oxidative stress, the liver tissue from ML385-treated mice demonstrated the highest content of MDA, whereas GSH and NADPH were markedly decreased compared with the ACLF group and controls (Figure 5(e)–5(g)). Taken together, targeting Nrf2 might hold a potential therapeutic value in treating ACLF.

3.4. Inhibiting Ferroptosis Attenuated the Severity of ACLF In Vivo. To confirm functions of ferroptosis in ACLF, ACLF mice were treated with ferroptosis-specific inhibitor Fer-1. Interestingly, Fer-1 ameliorated ACLF severity, manifesting with improved liver morphology and histopathologic lesions (e.g., reduced granules and improved lobule structure) (Figure 6(a)). Consistently, liver injury was revealed by critical indicators. Specifically, liver function indices (ALT and AST) in the Fer-1 treatment group were lower than that in the ACLF group, indicating a protective effect of Fer-1 on liver function (Figure 6(b)). Moreover, protein levels of hepatic inflammatory cytokines (IL-6 and TNF-α) were decreased in Fer-1-treated mice relative to the ACLF group (Figure 6(c)). Consistent with improved liver function, reduced lipid peroxidation was identified, evidenced by increased hepatic GSH and NADPH whereas decreased hepatic MDA in Fer-1-treated mice (Figures 6(d)–6(f)). Similarly, PTGS2 mRNA expression was reduced after Fer-1 treatment, indicating an improved lipid oxidative stress status (Figure 6(g)). In addition, TEM demonstrated improved ferroptosis-specific mitochondrial morphology after Fer-1 treatment (Figure 6(h)).

3.5. H₂O₂ Exposure Induced Ferroptosis in L02 Cells. To further explore engagement of ferroptosis in ACLF, a hepatocyte injury model was established via treating L02 cells with H₂O₂ for 30 h. Cells were divided into 4 groups as follows: control, ACLF, ACLF + Fer-1, and control + Erastin (E) (serving as the positive control). CCK-8 assay indicated that H₂O₂ inhibited cell viability, as exhibited in the control + E group, whereas Fer-1 reversed growth inhibition, as evidenced by improved viability in the ACLF+Fer-1 group (Figure 7(a)). L02 cells grew slowly and became skinnier, accompanied by decreased attachment following H₂O₂ and Erastin treatment. These cells eventually exhibited a “ballooning” phenotype because of plasma membrane destabilization, cytoskeletal rearrangements, and disruption of proteostasis [31]. By contrast, Fer-1 improved morphology (Figure 7(b)). H₂O₂ increased lipid ROS in a comparable pattern to Erastin treatment, which was counteracted by Fer-1 (Figure 7(c)). In parallel, compared with the control group, increased MDA whereas decreased GSH were
Figure 7: Continued.
observed in the H2O2 and Erastin treatment groups, which was rescued by Fer-1 (Figures 7(d) and 7(e)). Simultaneously, nuclear protein expression of Nrf2 was upregulated after H2O2 or Erastin treatment (Figure 7(f)). In addition, at protein (Supplementary Figure 2) and mRNA levels (Figure 7(g)), Nrf2 target genes heme oxygenase-1 (HO-1) and NQO1 were upregulated in response to H2O2 and Erastin treatment. Collectively, H2O2 treatment contributed to ferroptosis in L02 cells.

3.6. Nrf2 Protected against H2O2-Induced Hepatotoxicity via Inhibiting Ferroptosis In Vitro. To explore effects of Nrf2 on H2O2-induced cell injury, BM (0.2 μM) and ML385 (10 μM) were applied to activate or inhibit Nrf2. As shown in
Figure 8: Continued.
Figure 8(a), nuclear expression of Nrf2 was increased upon BM treatment whereas decreased upon ML385 treatment, suggesting that Nrf2 was activated or inactivated, respectively. The mRNA (Supplemental Figure 1) and protein expression (Supplemental Figure 2) of HO-1 and NQO1 changed accordingly in response to activation or inhibition of Nrf2, respectively. BM treatment improved cell viability and morphologic features, while ML385 treatment had opposite effects (Figures 8(b) and 8(c)). These results indicated that Nrf2 might exert a protective effect on H₂O₂-induced cell damage. Effects of Nrf2 on H₂O₂-induced ferroptosis were investigated in L02 cells. BM treatment decreased lipid peroxidation during ACLF, as evidenced by reduced level of lipid ROS in the BM treatment group relative to the ACLF group (Figure 8(d)). In contrast, ML385 treatment augmented the accumulation of lipid ROS. Likewise, ML385 treatment aggravated the increase in MDA whereas decrease in GSH in L02 cells (Figures 8(e) and 8(f)). Taken together, Nrf2 could protect L02 cells from H₂O₂-induced ferroptosis.

4. Discussion

In this study, ferroptosis has been identified to participate in pathogenesis of ACLF, while inhibition of ferroptosis through activating Nrf2-mediated pathway is a potential strategy to prevent ACLF progression. Characterized by a heterogeneous and intertwined pathophysiological process and high short-term mortality, ACLF constitutes a significant threat to public health worldwide without clinically...
effective treatments [32]. Unveiling ACLF pathogenesis and seeking effective therapeutic targets would be a focus of clinical and basic research. Here, through establishing ACLF models by treating mice with CCl₄, LPS, and D-Gal along with a hepatocyte injury model, for the first time we demonstrate participation of ferroptosis in ACLF pathogenesis as evidenced by the following: (1) ACLF livers exhibit key features of ferroptosis including lipid peroxidation ⁶ 2₃ (increase in MDA content whereas decrease in GSH and NADPH in ACLF models), upregulation of PTGS2, and presence of ferroptosis-specific mitochondrial morphology; (2) activation of ferroptosis exacerbates lipid peroxidation and leads to more severe liver damage, while inhibiting ferroptosis with ferroptosis inhibitor Fer-1 [8] largely abrogates injury and restores liver damage.

Ferroptosis is an iron-dependent nonapoptotic form of cell death resulting from excessive iron accumulation and lipid peroxidation. Massive iron accumulation, increased lipid peroxidation, and deficiency in cellular antioxidation are recognized as main pathological pillars during ferroptotic cascade [33]. Recently, accumulating evidence has indicated involvement of ferroptosis in liver diseases. Ferroptosis may contribute to liver injury and promote disease progression in acute or chronic liver diseases, such as ischemia/reperfusion-related injury and nonalcoholic fatty liver disease [8, 24]. Despite evidence that iron overload and increased oxidative stress have been revealed in ACLF patients, especially those with multiorgan failure [13, 14, 34, 35], no studies have investigated association between ferroptosis and ACLF, representing a gap in knowledge. For the first time, our current study has demonstrated that ferroptosis is responsible for aggravated liver damage in ACLF. Thus, inhibiting ferroptosis alleviates the severity of ACLF, providing novel therapeutic cues based on ferroptosis.

Nrf2 is a stress-inducible transcription factor that elicits defense to protect cells from oxidative injury through regulation of a host of defensive and detoxification genes [36] involved in iron metabolism, glutathione synthesis, and metabolism of reactive intermediates [37, 38]. Notably, most of its target genes are critical for ferroptosis. In addition, antiferroptosis mediators including glutathione peroxidase 4 (Gpx4) [39], Ferroptosis Suppressor Protein 1 (FSP1) [40], and system Xc⁻ [41] are all target genes of Nrf2. Thus, Nrf2-mediated antioxidant defense is integral in mitigating lipid peroxidation and ferroptosis prevention. For pathologic conditions where ferroptosis functions as a detrimental factor in disease development, activation of Nrf2 may play a beneficial role in attenuating damage through removing overwhelmed lipid peroxidation and unrelenting cell death [19]. For example, ferroptosis was activated after seawater drowning, and repression of ferroptosis relieved lung damage [30]. Further mechanical studies using inhibitor/inducer of Nrf2 suggested that activation of Nrf2 improved the severity of acute lung injury via decreasing lipid peroxidation [30].

In the present study, nuclear expression of Nrf2 was upregulated in ACLF model and hepatocyte injury model, implying that Nrf2 may activate adaptively to combat increased lipid peroxidation. The end products of lipid peroxidation themselves, including MDA and 4-hydroxynonenal (4-HNE), are potent initiators of lipid peroxidation [42]. As such, pharmacologically activated Nrf2 might have a synergistic effect with originally activated Nrf2 to control rapidly increased lipid peroxidation. To test this hypothesis, inhibitor/inducer of Nrf2 (ML385 and BM) was applied. As expected, BM treatment induced Nrf2 expression, improved cell viability, reduced MDA and lipid ROS, and restored depleted GSH in L02 cells after H₂O₂ exposure. As depicted in liver histopathology, BM treatment reduced histological lesions in ACLF mice. Mounting evidence has revealed the important role of Nrf2 in ameliorating inflammatory responses [43–46]. Consistently proinflammatory cytokines TNF-α and IL-6 were decreased in BM-treated mice compared with ACLF mice, suggesting a reduced inflammatory response. In addition, increased GSH and NADPH whereas decreased MDA and PTGS2 mRNA expression suggested that BM mitigated ferroptosis in vivo. Inhibitory effects of Nrf2 on ferroptosis were verified by using Nrf2 inhibitor ML385. As expected, ML385 exerted opposite effects to BM. Overall, Nrf2 could attenuate liver damage via inhibiting ferroptosis and inflammatory response in ACLF. Although inhibiting ferroptosis may have an anti-inflammatory effect [47], our current study observed no significant decrease in TNF-α and IL-6 in mice treated with ferroptosis inhibitor compared with ACLF mice. More research is needed to determine potential roles of ferroptosis in inflammatory response in ACLF. Previous studies indicated that BM might increase serum aminotransferase levels through inducing expression of aminotransferases as an on-target effect [48], which may partly explain why ALT and AST levels were not decreased after BM treatment in mice (Figure 3(f)).

Despite novel findings, some limitations of this study should be kept in mind. Bardoxolone Methyl is a potent noncytotoxic activator of Nrf2 and has been tested in clinical trials for chronic kidney and malignant diseases [49, 50]. However, because of multifunctional property such as an inhibitor nuclear factor-κB [51], precise net effects of Nrf2 on ferroptosis in ACLF should be examined via genetic manipulation of Nrf2. In addition, upstream regulators of Nrf2 in ACLF need investigation.

5. Conclusions

In summary, our present study provides the first evidence that ferroptosis is a major RCD in ACLF. Inhibiting ferroptosis by Nrf2 could alleviate liver damage and prevent hepatocyte death. This study implies that targeting Nrf2-mediated ferroptosis may be a promising therapeutic approach in treating ACLF. Bardoxolone Methyl may be a potential new treatment option for ACLF patients.

Data Availability

The data that support the findings of this study are available from the corresponding author upon reasonable request.
Conflicts of Interest

The authors declare that they have no competing interests.

Authors’ Contributions

J.W. and M.W. performed the experiments. J.W. and R.X. analyzed the data. J.W. wrote the first draft of the manuscript. B.X., J.W., M.W., X.Y., and R.X. participated in the critical discussion. Q.M. contributed to the research design and finalized the manuscript.

Acknowledgments

The study was supported by the National Science and Technology Major Project of China (Nos. 2018ZX10302206-003-007 and 2017ZX10203202-001-005), the Municipal Natural Science Foundation of Beijing, China, (No. 7192085), the Capital Health Research and Development of Special (No. 2018-1-3011), and National Natural Science Foundation of China (No. 82170643).

Supplementary Materials

Supplementary 1. Figure 1: the mRNA expression of Nrf2 target genes. A. The mRNA expression of NQO1 was upregulated in ACLF patients relative to healthy controls. (HC n = 3, ACLF n = 5). B. The mRNA expression of HO-1 was increased after H2O2 exposure, and BM treatment augmented its expression, while ML385 inhibited its expression (n = 3).

Supplementary 2. Figure 2: the protein expression of Nrf2 target genes. A. The protein expressions of NQO1 and HO-1 were increased in response to H2O2 and Erastin treatment, while Fer-1 treatment reversed the effect of H2O2 (n = 3). B. The protein expressions of HO-1 and NQO1 were increased after H2O2 exposure, and BM treatment augmented its expression, while ML385 inhibited its expression (n = 3). ACLF, acute-on-chronic liver failure; BM, Bardoxolone Methyl; E, Erastin; Fer-1, ferrostatin-1; HO-1, heme oxygenase-1; NQO1, NAD(P)H quinone dehydrogenase, quinone 1.

References

[1] S. K. Sarin and A. Choudhury, “Acute-on-chronic liver failure: terminology, mechanisms and management,” Nature Reviews Gastroenterology & Hepatology, vol. 13, no. 3, pp. 131–149, 2016.
[2] K. Sargentii, H. Prytz, E. Nilsson, and E. Kalaitzakis, “Predictors of mortality among patients with compensated and decompensated liver cirrhosis: the role of bacterial infections and infection-related acute-on-chronic liver failure,” Scandinavian Journal of Gastroenterology, vol. 50, no. 7, pp. 875–883, 2015.
[3] D. Adebayo, V. Morabito, F. Andreola et al., “Mechanism of cell death in acute-on-chronic liver failure: a clinicopathologic-biomarker study,” Liver International, vol. 35, no. 12, pp. 2564–2574, 2015.
[4] R. Xue, J. Yang, L. Jia et al., “Mitofusin2, as a protective target in the liver, controls the balance of apoptosis and autophagy in acute-on-chronic liver failure,” Frontiers in Pharmacology, vol. 10, p. 601, 2019.
[5] Y. Zou, T. Chen, M. Han et al., “Increased killing of liver NK cells by Fas/Fas ligand and NKG2D/NKG2D ligand contributes to hepatocyte necrosis in virus-induced liver failure,” The Journal of Immunology, vol. 184, no. 1, pp. 466–475, 2010.
[6] S. J. Dixon and B. R. Stockwell, “The hallmarks of ferroptosis,” Annual Review of Cancer Biology, vol. 3, no. 1, pp. 35–54, 2019.
[7] S. J. Dixon, K. M. Lemberg, M. R. Lamprecht et al., “Ferroptosis: an iron-dependent form of nonapoptotic cell death,” Cell, vol. 149, no. 5, pp. 1060–1072, 2012.
[8] J. Wu, Y. Wang, R. Jiang et al., “Ferroptosis in liver disease: new insights into disease mechanisms,” Cell Death Discovery, vol. 7, no. 1, pp. 1–9, 2021.
[9] B. R. Stockwell, X. Jiang, and W. Gu, “Emerging mechanisms and disease relevance of ferroptosis,” Trends in Cell Biology, vol. 30, no. 6, pp. 478–490, 2020.
[10] J. R. Wu, Q. Z. Tuo, and P. Lei, “Ferroptosis, a recent defined form of critical cell death in neurological disorders,” Journal of Molecular Neuroscience, vol. 66, no. 2, pp. 197–206, 2018.
[11] X. Fang, H. Wang, D. Han et al., “Ferroptosis as a target for protection against cardiomyopathy,” Proceedings of the National Academy of Sciences, vol. 116, no. 7, pp. 2672–2680, 2019.
[12] J. Wu and Q.-H. Meng, “Current understanding of the metabolism of micronutrients in chronic alcoholic liver disease,” World Journal of Gastroenterology, vol. 26, no. 31, pp. 4567–4578, 2020.
[13] J. S. Maras, R. Maiwall, H. Harsha et al., “Dysregulated iron homeostasis is strongly associated with multiorgan failure and early mortality in acute-on-chronic liver failure,” Hepatology, vol. 61, no. 4, pp. 1306–1320, 2015.
[14] T. Bruns, R. Nuraldeen, M. Mai et al., “Low serum transferrin correlates with acute-on-chronic organ failure and indicates short-term mortality in decompensated cirrhosis,” Liver International, vol. 37, no. 2, pp. 232–241, 2017.
[15] K. Taguchi and M. Yamamoto, “The KEAP1–NRF2 system as a molecular target of cancer treatment,” Cancers, vol. 13, no. 1, article 46, 2021.
[16] Q. Wang, C. Bin, Q. Xue et al., “GSTZ1 sensitizes hepatocellular carcinoma cells to sorafenib-induced ferroptosis via inhibition of NRF2/GPX4 axis,” Cell Death & Disease, vol. 12, no. 5, pp. 1–16, 2021.
[17] X. Sun, Z. Ou, R. Chen et al., “Activation of the p62-Keap1-NRF2 pathway protects against ferroptosis in hepatocellular carcinoma cells,” Hepatology, vol. 63, no. 1, pp. 173–184, 2016.
[18] C. Wang, T. Liu, Y. Tong et al., “Ulinastatin protects against acetaminophen-induced liver injury by alleviating ferroptosis via the SIRT1/NRF2/FOXO1 pathway,” American Journal of Translational Research, vol. 13, no. 6, pp. 6031–6042, 2021.
[19] G. Gao, Z. Xie, E. W. Li et al., “Dehydroabietic acid improves acute-on-chronic liver failure via the SIRT1/NRF2/HO-1 pathway,” Frontiers in Pharmacology, vol. 10, p. 601, 2019.
[20] S. K. Sarin, A. Choudhury, M. K. Sharma et al., “Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific association for the study of the liver (APASL): an update,” Hepatology International, vol. 13, no. 4, pp. 353–390, 2019.
[21] M. Wang, C.-Y. Liu, T. Wang et al., “(+)-Clausenamide protects against drug-induced liver injury by inhibiting...
hepatocyte ferroptosis,” *Cell Death & Disease*, vol. 11, no. 9, pp. 1–15, 2020.

[22] H. Wang, P. An, E. Xie et al., “Characterization of ferroptosis in murine models of hemochromatosis,” *Hepatology*, vol. 66, no. 2, pp. 449–465, 2017.

[23] K. Shimada, M. Hayano, N. C. Pagano, and B. R. Stockwell, “Cell-line selectivity improves the predictive power of pharmacogenomic analyses and helps identify NADPH as biomarker for ferroptosis sensitivity,” *Cell Chemical Biology*, vol. 23, no. 2, pp. 225–235, 2016.

[24] J. Qi, J.-W. Kim, Z. Zhou, C. W. Lim, and B. Kim, “Ferroptosis affects the progression of nonalcoholic steatohepatitis via the modulation of lipid peroxidation-mediated cell death in mice,” *The American Journal of Pathology*, vol. 190, no. 1, pp. 68–81, 2020.

[25] T. W. Kensler, N. Wakabayashi, and S. Biswal, “Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway,” *Annual Review of Pharmacology and Toxicology*, vol. 47, no. 1, pp. 89–116, 2007.

[26] Y. Lv, H. Jiang, S. Li et al., “Sulforaphane prevents chromium-induced lung injury in rats via activation of the Akt/GSK-3β/Fyn pathway,” *Environmental Pollution*, vol. 259, article 113812, 2020.

[27] D. Yang, Q. Yang, N. Fu et al., “Hexavalent chromium induced heart dysfunction via Sns2-mediated impairment of mitochondrial function and energy supply,” *Chemosphere*, vol. 264, no. 2, article 128547, 2021.

[28] A. K. Kalvala, R. Kumar, B. Sherkhane, C. Gundu, V. K. Arruri, and A. Kumar, “Bardoxolone methyl ameliorates hyperglycemia induced mitochondrial dysfunction by activating the keap1-Nrf2-ARE pathway in experimental diabetic neuropathy,” *Molecular Neurobiology*, vol. 57, no. 8, pp. 3616–3631, 2020.

[29] R. Wu, H. Zhang, M. Zhao et al., “Nrf2 in keratinocytes protects against skin fibrosis via regulating epidermal lesion and inflammatory response,” *Biochemical Pharmacology*, vol. 174, article 113846, 2020.

[30] Y. B. Qiu, B. B. Wan, G. Liu et al., “Nrf2 protects against seawater drowning-induced acute lung injury via inhibiting ferroptosis,” *Respiratory Research*, vol. 21, no. 1, pp. 1–16, 2020.

[31] M. Dodson, R. Castro-Portuguese, and D. D. Zhang, “NRF2 plays a critical role in mitigating lipid peroxidation and ferroptosis,” *Redox Biology*, vol. 23, article 101107, 2019.

[32] R. Hernaez, E. Solà, R. Moreau, and P. Ginès, “Acute-on-chronic liver failure: an update,” *Gut*, vol. 66, no. 3, pp. 541–553, 2017.

[33] W. S. Yang and B. R. Stockwell, “Ferroptosis: death by lipid peroxidation,” *Trends in Cell Biology*, vol. 26, no. 3, pp. 165–176, 2016.

[34] G. R. Assis-Mendoça, M. Cunha-Silva, M. F. Fernandes et al., “Massive iron overload and acute-on-chronic liver failure in a patient with Diamond–Blackfan anemia: a case report,” *BMC Gastroenterology*, vol. 20, no. 1, pp. 1–7, 2020.

[35] H. Liu, T. Han, J. Tian et al., “Monitoring oxidative stress in acute-on-chronic liver failure by advanced oxidation protein products,” *Hepatology Research*, vol. 42, no. 2, pp. 171–180, 2012.

[36] G. M. DeNicola, F. A. Karreth, T. J. Humphton et al., “Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis,” *Nature*, vol. 475, no. 7354, pp. 106–109, 2011.

[37] J. D. Hayes and A. T. Dinkova-Kostova, “The Nrf2 regulatory network provides an interface between redox and intermediary metabolism,” *Trends in Biochemical Sciences*, vol. 39, no. 4, pp. 199–218, 2014.

[38] J. Y. Chan and M. Kwong, “Impaired expression of glutathione synthetic enzyme genes in mice with targeted deletion of the Nrf2 basic–leucine zipper protein,” *Biochimica et Biophysica Acta (BBA)-Gene Structure and Expression*, vol. 1517, no. 1, pp. 19–26, 2000.

[39] Q. Liu and K. Wang, “The induction of ferroptosis by impairing STAT3/Nrf2/GPx4 signaling enhances the sensitivity of osteosarcoma cells to cisplatin,” *Cell Biology International*, vol. 43, no. 11, pp. 1245–1256, 2019.

[40] B. N. Chorley, M. R. Campbell, X. Wang et al., “Identification of novel Nrf2-regulated genes by ChIP-Seq: influence on retinoid X receptor alpha,” *Nucleic Acids Research*, vol. 40, no. 15, pp. 7416–7429, 2012.

[41] L. Feng, K. Zhao, L. Sun et al., “SLC7A11 regulated by Nrf2 modulates esophageal squamous cell carcinoma radiosensitivity by inhibiting ferroptosis,” *Journal of Translational Medicine*, vol. 19, no. 1, pp. 1–16, 2021.

[42] H. Yin, L. Xu, and N. A. Porter, “Free radical lipid peroxidation: mechanisms and analysis,” *Chemical Reviews*, vol. 111, no. 10, pp. 5944–5972, 2011.

[43] H. Lu, X. Sun, M. Jia et al., “Rosiglitazone suppresses renal crystal deposition by ameliorating tubular injury resulted from oxidative stress and inflammatory response via promoting the Nrf2/HO-1 pathway and shifting macrophage polarization,” *Oxidative Medicine and Cellular Longevity*, vol. 2021, 19 pages, 2021.

[44] X. Wang, Z. Lv, B. Han et al., “The aggravation of allergic airway inflammation with dibuty l phthalate involved in Nrf2-mediated activation of the mast cells,” *Science of The Total Environment*, vol. 789, article 148029, 2021.

[45] Q. Yang, B. Han, S. Li et al., “The link between deacetylation and hepatotoxicity induced by exposure to hexavalent chromium,” *Journal of Advanced Research*, vol. 35, pp. 129–140, 2022.

[46] N. Deng, H. Jiang, P. Wu et al., “Inhibition of the Nrf2/p38MAPK pathway involved in deltamethrin-induced apoptosis and fibrosis in quail kidney,” *Food and Chemical Toxicology*, vol. 155, article 112382, 2021.

[47] Y. Sun, P. Chen, B. Zhai et al., “The emerging role of ferroptosis in inflammation,” *Biomedicine & Pharmacotherapy*, vol. 127, article 110108, 2020.

[48] R. J. Church and P. B. Watkins, “The challenge of interpreting alanine aminotransferase elevations in clinical trials of new drug candidates,” *Clinical and Translational Science*, vol. 14, no. 2, pp. 434–436, 2021.

[49] D. S. Hong, R. Kurzrock, J. G. Supko et al., “A phase I human trial of bardoxolone methyl in patients with advanced solid tumors and lymphomas,” *Clinical Cancer Research*, vol. 18, no. 12, pp. 3396–3406, 2012.

[50] D. De Zeeuw, T. Akizawa, P. Audhya et al., “Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease,” *New England Journal of Medicine*, vol. 369, no. 26, pp. 2492–2503, 2013.

[51] Y. Y. Wang, Y. X. Yang, H. Zhe, Z. K. He, and S. F. Zhou, “Bardoxolone methyl (CDDO-Me) as a therapeutic agent: an update on its pharmacokinetic and pharmacodynamic properties,” *Drug Design, Development and Therapy*, vol. 8, pp. 2075–2088, 2014.